Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Carboplatin + Nab-paclitaxel + Pembrolizumab |
Indication/Tumor Type | lung squamous cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung squamous cell carcinoma | sensitive | Carboplatin + Nab-paclitaxel + Pembrolizumab | Guideline | Actionable | Combination Paraplatin (carboplatin), Abraxane (nab-paclitaxel), and Keytruda (pembrolizumab) is in guidelines as preffered first-line therapy for patients with advanced or metastatic lung squamous cell carcinoma with CD274 (PD-L1) expression of greater than or equal to 1% and negative for actionable molecular biomarkers (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |